Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.

Related Keywords

Florida ,United States ,Tampa ,Anita Giobbie Hurder ,Zeynep Eroglu ,Genentech Roche ,Elsevier ,Novartis ,Boehringer Ingelheim ,Pfizer ,Department Of Oncologic Sciences ,Cutaneous Oncology ,Moffitt Cancer Center ,Oncologic Sciences ,South Florida Morsani College ,Dabrafenib ,Navitoclax ,Trametinib ,Melanoma ,Asco Annual Meeting ,Nct01989585 ,Ctep P9466 ,